

Amendments to the Claims:

Please cancel claims 1-49 and add claims 50-71 as follows:

50. (New) A method for treating a subject, comprising:
administering paliperidone to said subject; and
maintaining an ascending release rate of said paliperidone over a prolonged period of time.
51. (New) The method of claim 50, wherein said ascending release rate is maintained for about 10 to about 24 hours after administration.
52. (New) The method of claim 50, wherein said ascending release rate is maintained for about 16 to about 22 hours after administration.
53. (New) The method of claim 50, wherein said ascending release rate is maintained for about 18 to about 21 hours after administration.
54. (New) The method of claim 50, wherein said C_{\max} occurs at about 14 hours after administration.
55. (New) The method of claim 50, wherein said C_{\max} occurs at about 16 hours to about 22 hours after administration.
56. (New) The method of claim 50, wherein said C_{\max} occurs at about 18 hours to about 21 hours after administration.
57. (New) The method of claim 50, wherein T_{90} occurs at about 18 to about 22 hours after administration.
58. (New) The method of claim 50, wherein said administering paliperidone comprises administering paliperidone once a day.

59. (New) The method of claim 50, wherein said treating comprises reducing side effects associated with high blood plasma concentration of antipsychotic agents.
60. (New) The method of claim 59, wherein said side effects are selected from the group consisting of anxiety, somnolence, dizziness, constipation and extrapyramidal symptoms.
61. (New) A method for treating a subject, comprising:
administering paliperidone to said subject; and
maintaining a minimum pharmacodynamic concentration of said paliperidone while simultaneously maintaining an amount that does not exceed a maximum tolerable concentration of said paliperidone.
62. (New) A method for treating a subject, comprising:
administering paliperidone to said subject; and
maintaining a ratio of C_{\max} /dose of said paliperidone of less than about 30.
63. (New) A dosage form, comprising:
two or more layers, said two or more layers comprising a first layer and a second layer, said first layer comprises paliperidone, said second layer comprises a polymer;
an outer wall surrounding said two or more layers; and
an orifice in said outer wall.
64. (New) The dosage form of claim 63, wherein said first layer comprises an osmagent.
65. (New) The dosage form of claim 64, wherein said osmagent is sodium chloride.
66. (New) The dosage form of claim 64, wherein said osmagent is present at least 20% by weight in said first layer.

67. (New) The dosage form of claim 63, wherein said second layer further comprises paliperidone, an amount of paliperidone in said first layer to an amount of paliperidone in said second layer is less than 1.0.
68. (New) The dosage form of claim 67, wherein an amount of paliperidone in said first layer to an amount of paliperidone in said second layer is less than 0.44.
69. (New) The dosage form of claim 68, wherein amount of paliperidone in said first layer to an amount of paliperidone in said second layer is less than 0.33.
70. (New) The dosage form of claim 63, further comprising a subcoat surrounding said first layer and said second layer and within said outer wall.
71. The dosage form of claim 63, wherein said subcoat comprises a hydroxyalkylcellulose polymer having a molecular weight from about 8,500 to about 4,000,000.